Abstract:NALFD is becoming a global epidemic with severe complications, but few if any pharmacological therapies are available. Owing to its unique anatomy, microarchitecture, and cellular composition, the liver functions as an immune organ in addition to its roles in metabolism and detoxification. Innate immune signaling controls both inflammatory and metabolic profiles in the liver, and has potential to provide novel therapeutic targets in non-alcoholic steatohepatitis (NASH). Innate immune components mediate both canonical inflammation cascades and noncanonical metabolism-related pathways by modulating post-translational modifications or transcriptional coregulation, thus controlling NASH progression. Multi-omic analyses, cell signaling, and tissue-specific gene-editing technologies, combined with advances in disease models, will facilitate in-depth understanding of NAFLD and the discovery of new drugs. Non-alcoholic fatty liver disease (NAFLD) has become the most epidemic liver disease worldwide owing to rapid changes in lifestyle over the past few decades. This chronic condition intertwines with low-grade inflammation and metabolic disequilibrium, and potentiates the onset and progression of devastating hepatic and extrahepatic complications. In addition to an integral role in promoting host defense, recent studies also implicate innate immune signaling in a multitude of processes that control the progression of NAFLD. The focus of this review is to highlight emerging evidence regarding the role of innate immunity in NAFLD and the integration of different pathways that affect both inflammation and metabolism across the spectrum of this liver morbidity. Non-alcoholic fatty liver disease (NAFLD) has become the most epidemic liver disease worldwide owing to rapid changes in lifestyle over the past few decades. This chronic condition intertwines with low-grade inflammation and metabolic disequilibrium, and potentiates the onset and progression of devastating hepatic and extrahepatic complications. In addition to an integral role in promoting host defense, recent studies also implicate innate immune signaling in a multitude of processes that control the progression of NAFLD. The focus of this review is to highlight emerging evidence regarding the role of innate immunity in NAFLD and the integration of different pathways that affect both inflammation and metabolism across the spectrum of this liver morbidity.

Nuclear Receptors and Non-Alcoholic Fatty Liver Disease: an Update

Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities

Nuclear Receptors and Transcriptional Regulation in Non-Alcoholic Fatty Liver Disease

Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease

Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease

Application of Nuclear Receptor in Pathogenesis Research and Drug Development for Nonalcoholic Fatty Liver Disease

A new perspective on NAFLD: Focusing on the crosstalk between peroxisome proliferator-activated receptor alpha (PPARα) and farnesoid X receptor (FXR)

Lipid sensing nuclear receptors involved in the pathogenesis of fatty liver disease

Nuclear receptor-mediated hepatomegaly and liver regeneration: an update

Advances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease

Role of Noncoding RNA in Development of Nonalcoholic Fatty Liver Disease

The Role and Mechanism of Oxidative Stress and Nuclear Receptors in the Development of NAFLD

Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases

Role of Innate Immune Signaling in Non-Alcoholic Fatty Liver Disease

Is Nrf2-ARE a Potential Target in NAFLD Mitigation?

Fatty Liver Diseases, Bile Acids, and FXR

Targeting Liver X Receptors for the Treatment of Non-Alcoholic Fatty Liver Disease

Emerging novel targets for nonalcoholic fatty liver disease treatment: Evidence from recent basic studies

A Current Understanding of FXR in NAFLD: The multifaceted regulatory role of FXR and novel lead discovery for drug development

Nuclear receptors: pathophysiological mechanisms and drug targets in liver disease

Non-alcoholic fatty liver disease: An expanded review